Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02675426




Registration number
NCT02675426
Ethics application status
Date submitted
11/12/2015
Date registered
5/02/2016
Date last updated
11/04/2023

Titles & IDs
Public title
A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone
Scientific title
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs
Secondary ID [1] 0 0
2015-003332-13
Secondary ID [2] 0 0
M13-549
Universal Trial Number (UTN)
Trial acronym
SELECT-NEXT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Upadacitinib

Experimental: Upadacitinib 15 mg - Period 1: Participants receive upadacitinib 15 mg once daily for 12 weeks.

Period 2: Participants continue to receive upadacitinib 15 mg once daily for an additional 248 weeks.

Experimental: Upadacitinib 30 mg - Period 1: Participants receive upadacitinib 30 mg once daily for 12 weeks.

Period 2: Participants continue to receive upadacitinib 30 mg once daily for an additional 248 weeks or until implementation of Protocol Amendment 6 at which time participants switch to receive upadacitinib 15 mg once daily.

Experimental: Placebo / Upadacitinib 15 mg - Period 1: Participants receive placebo once daily for 12 weeks.

Period 2: Participants receive upadacitinib 15 mg once daily for 248 weeks.

Experimental: Placebo / Upadacitinib 30 mg - Period 1: Participants receive placebo once daily for 12 weeks.

Period 2: Participants receive upadacitinib 30 mg once daily for 248 weeks or until implementation of Protocol Amendment 6 at which time participants switch to receive upadacitinib 15 mg once daily.


Treatment: Drugs: Placebo
Tablet; Oral

Treatment: Drugs: Upadacitinib
Tablet; Oral
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
Timepoint [1] 0 0
Baseline and Week 12
Primary outcome [2] 0 0
Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12
Timepoint [2] 0 0
Week 12
Secondary outcome [1] 0 0
Change From Baseline in in Disease Activity Score 28 (CRP) at Week 12
Timepoint [1] 0 0
Baseline and Week 12
Secondary outcome [2] 0 0
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12
Timepoint [2] 0 0
Baseline and Week 12
Secondary outcome [3] 0 0
Change From Baseline in Short-Form 36 (SF-36) Physical Component Summary (PCS) Score at Week 12
Timepoint [3] 0 0
Baseline and Week 12
Secondary outcome [4] 0 0
Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) at Week 12
Timepoint [4] 0 0
Week 12
Secondary outcome [5] 0 0
Percentage of Participants Achieving Low Disease Activity Based on CDAI at Week 12
Timepoint [5] 0 0
Week 12
Secondary outcome [6] 0 0
Change From Baseline in Duration of Morning Stiffness at Week 12
Timepoint [6] 0 0
Baseline and Week 12
Secondary outcome [7] 0 0
Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Week 12
Timepoint [7] 0 0
Baseline and week 12
Secondary outcome [8] 0 0
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12
Timepoint [8] 0 0
Baseline and Week 12
Secondary outcome [9] 0 0
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12
Timepoint [9] 0 0
Baseline and Week 12
Secondary outcome [10] 0 0
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1
Timepoint [10] 0 0
Baseline and Week 1

Eligibility
Key inclusion criteria
* Adult male or female, at least 18 years old.
* Diagnosis of rheumatoid arthritis (RA) for greater than or equal to 3 months.
* Subjects have been receiving conventional synthetic DMARD (csDMARD) therapy for greater than or equal to 3 months and on a stable dose for greater than or equal to 4 weeks prior to the first dose of study drug. The following csDMARDs are allowed: methotrexate (MTX), sulfasalazine, hydroxychloroquine, chloroquine, and leflunomide.
* Meets the following minimum disease activity criteria: greater than or equal to 6 swollen joints (based on 66 joint counts) and greater than or equal to 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits.
* Subjects with prior exposure to at most one biologic DMARD (bDMARD) may be enrolled (up to 20% of study population) if they have documented evidence of intolerance to bDMARDs or limited exposure (less than 3 months) and have satisfied required washout periods.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib).
* History of inflammatory joint disease other than RA. History of secondary Sjogren's Syndrome is permitted.
* Subjects who are considered inadequate responders to bDMARD therapy as determined by the Investigator.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
17/12/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
10/03/2022
Sample size
Target
Accrual to date
Final
661
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Coffs Clinical Trials /ID# 138747 - Coffs Harbour
Recruitment hospital [2] 0 0
Optimus Clinical Research Pty. /ID# 138769 - Kogarah
Recruitment hospital [3] 0 0
Emeritus Research /ID# 138773 - Camberwell
Recruitment hospital [4] 0 0
Barwon Rheumatology /ID# 138772 - Geelong
Recruitment postcode(s) [1] 0 0
2450 - Coffs Harbour
Recruitment postcode(s) [2] 0 0
2217 - Kogarah
Recruitment postcode(s) [3] 0 0
3124 - Camberwell
Recruitment postcode(s) [4] 0 0
3220 - Geelong
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Idaho
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Maine
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Michigan
Country [13] 0 0
United States of America
State/province [13] 0 0
Nebraska
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oklahoma
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
South Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Washington
Country [23] 0 0
United States of America
State/province [23] 0 0
Wisconsin
Country [24] 0 0
Argentina
State/province [24] 0 0
Buenos Aires
Country [25] 0 0
Argentina
State/province [25] 0 0
Cordoba
Country [26] 0 0
Austria
State/province [26] 0 0
Vienna
Country [27] 0 0
Austria
State/province [27] 0 0
Wien
Country [28] 0 0
Belgium
State/province [28] 0 0
Hainaut
Country [29] 0 0
Belgium
State/province [29] 0 0
Oost-Vlaanderen
Country [30] 0 0
Belgium
State/province [30] 0 0
Brugge
Country [31] 0 0
Bosnia and Herzegovina
State/province [31] 0 0
Republika Srpska
Country [32] 0 0
Bulgaria
State/province [32] 0 0
Sofia
Country [33] 0 0
Canada
State/province [33] 0 0
Manitoba
Country [34] 0 0
Canada
State/province [34] 0 0
Newfoundland and Labrador
Country [35] 0 0
Canada
State/province [35] 0 0
Quebec
Country [36] 0 0
Canada
State/province [36] 0 0
Saskatchewan
Country [37] 0 0
Croatia
State/province [37] 0 0
Primorsko-goranska Zupanija
Country [38] 0 0
Croatia
State/province [38] 0 0
Zagreb
Country [39] 0 0
Czechia
State/province [39] 0 0
Moravskoslezsky Kraj
Country [40] 0 0
Czechia
State/province [40] 0 0
Brno
Country [41] 0 0
Czechia
State/province [41] 0 0
Ostrava
Country [42] 0 0
Czechia
State/province [42] 0 0
Slany
Country [43] 0 0
Czechia
State/province [43] 0 0
Zlin
Country [44] 0 0
Estonia
State/province [44] 0 0
Harjumaa
Country [45] 0 0
Estonia
State/province [45] 0 0
Pärnu
Country [46] 0 0
Estonia
State/province [46] 0 0
Tallinn
Country [47] 0 0
Finland
State/province [47] 0 0
Helsinki
Country [48] 0 0
Finland
State/province [48] 0 0
Hyvinkaa
Country [49] 0 0
Finland
State/province [49] 0 0
Lappeenranta
Country [50] 0 0
France
State/province [50] 0 0
Bouches-du-Rhone
Country [51] 0 0
France
State/province [51] 0 0
Chambray Les Tours
Country [52] 0 0
Germany
State/province [52] 0 0
Nordrhein-Westfalen
Country [53] 0 0
Germany
State/province [53] 0 0
Berlin
Country [54] 0 0
Germany
State/province [54] 0 0
Hamburg
Country [55] 0 0
Germany
State/province [55] 0 0
Planegg
Country [56] 0 0
Greece
State/province [56] 0 0
Heraklion
Country [57] 0 0
Hong Kong
State/province [57] 0 0
Sha Tin
Country [58] 0 0
Hungary
State/province [58] 0 0
Budapest
Country [59] 0 0
Hungary
State/province [59] 0 0
Szekesfehervar
Country [60] 0 0
Ireland
State/province [60] 0 0
Dublin
Country [61] 0 0
Italy
State/province [61] 0 0
Calabria
Country [62] 0 0
Kazakhstan
State/province [62] 0 0
Astana
Country [63] 0 0
Korea, Republic of
State/province [63] 0 0
Gwang Yeogsi
Country [64] 0 0
Korea, Republic of
State/province [64] 0 0
Gyeonggido
Country [65] 0 0
Korea, Republic of
State/province [65] 0 0
Jeonranamdo
Country [66] 0 0
Korea, Republic of
State/province [66] 0 0
Seongdong-gu
Country [67] 0 0
Korea, Republic of
State/province [67] 0 0
Seoul Teugbyeolsi
Country [68] 0 0
Korea, Republic of
State/province [68] 0 0
Daegu
Country [69] 0 0
Korea, Republic of
State/province [69] 0 0
Daejeon
Country [70] 0 0
Korea, Republic of
State/province [70] 0 0
Seoul
Country [71] 0 0
Latvia
State/province [71] 0 0
Adazi
Country [72] 0 0
Lithuania
State/province [72] 0 0
Klaipeda
Country [73] 0 0
Lithuania
State/province [73] 0 0
Vilnius
Country [74] 0 0
Mexico
State/province [74] 0 0
Yucatan
Country [75] 0 0
Mexico
State/province [75] 0 0
Mexico City
Country [76] 0 0
New Zealand
State/province [76] 0 0
Nelson
Country [77] 0 0
Poland
State/province [77] 0 0
Kujawsko-pomorskie
Country [78] 0 0
Poland
State/province [78] 0 0
Mazowieckie
Country [79] 0 0
Poland
State/province [79] 0 0
Podlaskie
Country [80] 0 0
Poland
State/province [80] 0 0
Warminsko-mazurskie
Country [81] 0 0
Poland
State/province [81] 0 0
Warsaw
Country [82] 0 0
Portugal
State/province [82] 0 0
Lisboa
Country [83] 0 0
Puerto Rico
State/province [83] 0 0
San Juan
Country [84] 0 0
Romania
State/province [84] 0 0
Cluj
Country [85] 0 0
Romania
State/province [85] 0 0
Ploiesti
Country [86] 0 0
Romania
State/province [86] 0 0
Sibiu
Country [87] 0 0
Russian Federation
State/province [87] 0 0
Stavropol Skiy Kray
Country [88] 0 0
Russian Federation
State/province [88] 0 0
Tatarstan, Respublika
Country [89] 0 0
Russian Federation
State/province [89] 0 0
Petrozavodsk
Country [90] 0 0
Russian Federation
State/province [90] 0 0
Samara
Country [91] 0 0
Russian Federation
State/province [91] 0 0
Ulyanovsk
Country [92] 0 0
Russian Federation
State/province [92] 0 0
Voronezh
Country [93] 0 0
Russian Federation
State/province [93] 0 0
Yaroslavl
Country [94] 0 0
Slovakia
State/province [94] 0 0
Kosice
Country [95] 0 0
Slovakia
State/province [95] 0 0
Pieštany
Country [96] 0 0
Slovakia
State/province [96] 0 0
Trnava
Country [97] 0 0
South Africa
State/province [97] 0 0
Kwazulu-Natal
Country [98] 0 0
South Africa
State/province [98] 0 0
Western Cape
Country [99] 0 0
Spain
State/province [99] 0 0
Malaga
Country [100] 0 0
Spain
State/province [100] 0 0
Elche
Country [101] 0 0
Spain
State/province [101] 0 0
Madrid
Country [102] 0 0
Spain
State/province [102] 0 0
Santiago de Compostela
Country [103] 0 0
Switzerland
State/province [103] 0 0
Fribourg
Country [104] 0 0
Taiwan
State/province [104] 0 0
Taichung
Country [105] 0 0
Taiwan
State/province [105] 0 0
Tainan
Country [106] 0 0
Taiwan
State/province [106] 0 0
Taipei
Country [107] 0 0
Taiwan
State/province [107] 0 0
Kaohsiung
Country [108] 0 0
Taiwan
State/province [108] 0 0
New Taipei City
Country [109] 0 0
Taiwan
State/province [109] 0 0
Taipei City
Country [110] 0 0
Turkey
State/province [110] 0 0
Ankara
Country [111] 0 0
Ukraine
State/province [111] 0 0
Kyiv
Country [112] 0 0
Ukraine
State/province [112] 0 0
Lviv
Country [113] 0 0
Ukraine
State/province [113] 0 0
Odesa
Country [114] 0 0
United Kingdom
State/province [114] 0 0
England
Country [115] 0 0
United Kingdom
State/province [115] 0 0
London, City Of
Country [116] 0 0
United Kingdom
State/province [116] 0 0
Edinburgh
Country [117] 0 0
United Kingdom
State/province [117] 0 0
Southampton
Country [118] 0 0
United Kingdom
State/province [118] 0 0
Warrington

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AbbVie
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objectives of this study are to compare the efficacy, safety, and tolerability of upadacitinib 30 mg once daily (QD) and 15 mg QD versus placebo for the treatment of signs and symptoms of adults with moderately to severely active rheumatoid arthritis who were on a stable dose of csDMARDs and had an inadequate response to csDMARDs.
Trial website
https://clinicaltrials.gov/study/NCT02675426
Trial related presentations / publications
Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, Zhou Y, Othman AA, Pangan AL, Camp HS. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018 Jun 23;391(10139):2503-2512. doi: 10.1016/S0140-6736(18)31115-2. Epub 2018 Jun 18.
Bergman M, Buch MH, Tanaka Y, Citera G, Bahlas S, Wong E, Song Y, Zueger P, Ali M, Strand V. Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials. Rheumatol Ther. 2022 Dec;9(6):1517-1529. doi: 10.1007/s40744-022-00483-4. Epub 2022 Sep 20.
Bergman M, Tundia N, Yang M, Orvis E, Clewell J, Bensimon A. Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis. Adv Ther. 2021 Dec;38(12):5649-5661. doi: 10.1007/s12325-021-01930-4. Epub 2021 Oct 12.
Yamaoka K, Tanaka Y, Kameda H, Khan N, Sasaki N, Harigai M, Song Y, Zhang Y, Takeuchi T. The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. Drug Saf. 2021 Jun;44(6):711-722. doi: 10.1007/s40264-021-01067-x. Epub 2021 May 27.
Cohen SB, van Vollenhoven RF, Winthrop KL, Zerbini CAF, Tanaka Y, Bessette L, Zhang Y, Khan N, Hendrickson B, Enejosa JV, Burmester GR. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2021 Mar;80(3):304-311. doi: 10.1136/annrheumdis-2020-218510. Epub 2020 Oct 28. Erratum In: Ann Rheum Dis. 2021 May;80(5):e83. doi: 10.1136/annrheumdis-2020-218510corr1.
Strand V, Pope J, Tundia N, Friedman A, Camp HS, Pangan A, Ganguli A, Fuldeore M, Goldschmidt D, Schiff M. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. Arthritis Res Ther. 2019 Dec 9;21(1):272. doi: 10.1186/s13075-019-2037-1. Erratum In: Arthritis Res Ther. 2020 Jun 9;22(1):137. doi: 10.1186/s13075-020-02238-4.
Nader A, Mohamed MF, Winzenborg I, Doelger E, Noertersheuser P, Pangan AL, Othman AA. Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis. Clin Pharmacol Ther. 2020 Apr;107(4):994-1003. doi: 10.1002/cpt.1671. Epub 2019 Nov 30.
Public notes

Contacts
Principal investigator
Name 0 0
AbbVie Inc.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02675426